164 - Effectiveness of Adjuvanted Inactivated Influenza Vaccine versus High-Dose Inactivated Influenza Vaccine Against PCR-Confirmed Influenza among Adults ≥65 years: A Pragmatic Randomized Study

Thursday, October 17, 2024

1:45 PM – 1:57 PM US PT

Location: 403 A

Co-Author(s)

AH

Amber Hsiao, MPH

Senior Research Project Manager
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
AY

Arnold Yee, MA

Senior Data Consultant
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
TL

Thomas Leong, MPH

Kaiser Permanente Northern California
Oakland, California, United States
Ousseny Zerbo, PhD

Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, CA, United States
BF

Bruce Fireman, MA

Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
KJ

Karen B. Jacobson, MD, MPH

Kaiser Permanente Vaccine Study Center
Oakland, California, United States
John R. Hansen, MPH

Group Leader Consulting
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
EL

Evan Layefsky, BA

Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States
MH

Mendel Haag, PhD, PharmD

CSL Seqirus
Amsterdam, Noord-Holland, Netherlands
Ian McGovern, MPH (he/him/his)

Associate Director, Center for Outcomes Research and Epidemiology
CSL Seqirus
Waltham, Massachusetts, United States
BZ

Bin Zhang, ScD, MA

CSL Seqirus
Waltham, Massachusetts, United States
JD

Juliet Dang, PhD, MS

CSL Seqirus
Summit, New Jersey, United States

Presenting Author(s)

Nicola P. Klein, MD, PhD (she/her/hers)

Director, Kaiser Permanente Vaccine Study Center and Senior Research Scientist
Division of Research Kaiser Permanente Vaccine Study Center
Oakland, California, United States

Slides

Disclosure(s):

Amber Hsiao, MPH: No financial relationships to disclose

Arnold Yee, MA: No financial relationships to disclose

Ousseny Zerbo, PhD: No financial relationships to disclose

Mendel Haag, PhD, PharmD: CSL Seqirus: Employee, Stocks/Bonds (Public Company)

Ian McGovern, MPH: CSL Seqirus: employee, Stocks/Bonds (Public Company)

Bin Zhang, ScD, MA: CSL Seqirus: Employee, Stocks/Bonds (Public Company)

Juliet Dang, PhD, MS: CSL Seqirus: Employee, Stocks/Bonds (Public Company)

Nicola P. Klein, MD, PhD: GlaxoSmithKline: Grant/Research Support; Merck: Grant/Research Support; Pfizer: Grant/Research Support; Sanofi Pasteur: Grant/Research Support; Seqirus: Grant/Research Support